血尿酸、MMP-3水平与银杏达莫注射液治疗大动脉粥样硬化型缺血性脑卒中疗效的相关性

目的 分析血尿酸、基质金属蛋白酶-3（MMP-3）水平与银杏达莫注射液辅助治疗大动脉粥样硬化型缺血型脑卒中疗效的相关性，并评估血清各项指标预测疗效的价值。方法 回顾性分析2018年2月—2019年11月于沧州市中心医院接受银杏达莫注射液辅助治疗的82例大动脉粥样硬化型缺血性脑卒中患者的临床资料，根据疗效分为A组（基本治愈）、B组（显效）、C组（有效）和D组（无效）。检测并比较各组血尿酸、MMP-3、同型半胱氨酸（Hcy）、白细胞介素-10（IL-10）水平，分析血清各项指标与疗效的相关性，绘制受试者工作特征（ROC）曲线，检验各指标用于预测疗效的价值。结果 血尿酸、MMP-3、Hcy水平D组>C组>B组>A组（P <0.05）；IL-10水平D组<C组<B组<A组（P <0.05）。血尿酸、MMP-3及Hcy与疗效呈负相关（r =-0.524、-0.486和-0.245，均P <0.05）；IL-10与疗效呈正相关（r =0.781，P <0.05）。ROC曲线结果显示，血尿酸、MMP-3、Hcy、IL-10预测银杏达莫注射液辅助治疗大动脉粥样硬化型缺血性脑卒中疗效的敏感性分别为0.902、0.845、0.713、0.685，特异性分别为0.785、0.781、0.684、0.684。结论 血尿酸、MMP-3水平可作为预测银杏达莫注射液辅助治疗大动脉粥样硬化型缺血性脑卒中疗效的血清学指标，且两者水平与疗效呈负相关，故临床治疗时需积极调节患者血尿酸、MMP-3水平。

Relationship between serum UA, MMP-3 level and curative effect of ginkgo leaf extract and dipyridamole in treatment of large artery atherosclerotic ischemic stroke

Objective To analyze the correlation between serum uric acid (UA) and matrix metalloproteinase-3 (MMP-3) levels and the efficacy of GINKGO dipyridamole in the treatment of large atherosclerotic ischemic stroke, and to evaluate the value of serum indicators to predict the efficacy.Methods The clinical data of 82 patients with aortic ischemic stroke who were treated with GINKGO dipyridamole in our hospital from February 2018 to November 2019 were retrospectively analyzed and divided into group A (Basic cure, n = 18), group B (significant effect, n = 35), group C (effective, n = 20), and group D (ineffective, n = 9), according to the treatment effect. Serum levels of UA, MMP-3, homocysteine, and interleukin-10 (IL-10) were measured and compared in each group. The receiver operating characteristic curve (ROC) was drawn to test the value of each index used to predict the curative effect.Results Levels of UA, MMP-3, and Hcy in group D > group C > group B > group A, and IL-10 level in group D < group C < group B < group A, with the difference is statistically significant (P < 0.05); uric acid, MMP-3, and Hcy levels were negatively correlated with the efficacy (r =-0.524, -0.486, -0.245, all P < 0.05), and IL-10 was positively correlated with the efficacy (r = 0.781, P < 0.05); the sensitivity of uric acid, MMP-3, Hcy, and IL-10 to predict the therapeutic effect of ginkgo dipyridamole on ischemic stroke was 0.902, 0.845, 0.713, and 0.685, respectively, and the specificity were 0.785, 0.781, 0.684, and 0.684, respectively.Conclusions Serum UA and MMP-3 levels can be used as serological indicators to predict the efficacy of GINKGO dipyridamole in the treatment of aortic atherosclerotic ischemic stroke, and the levels of the two are negatively correlated with the curative effect. Hence, it is necessary to actively adjust the serum UA and MMP-3 levels of patients during clinical treatment.